Sentence: A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Afatinib', 'Nimotuzumab'], 'is_context_needed': True}]